Dechra Pharmaceuticals plc Receives Buy Rating from FinnCap (DPH)
Dechra Pharmaceuticals plc (LON:DPH)‘s stock had its “buy” rating reaffirmed by equities researchers at FinnCap in a research report issued on Tuesday. They currently have a GBX 800 ($13.72) price objective on the stock. FinnCap’s price objective would suggest a potential upside of 9.59% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Investec raised their price target on shares of Dechra Pharmaceuticals plc from GBX 787 ($13.50) to GBX 842 ($14.44) in a research note on Wednesday, June 11th. They now have a “buy” rating on the stock. Separately, analysts at Panmure Gordon reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Thursday, June 5th. They now have a GBX 850 ($14.58) price target on the stock. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of GBX 781 ($13.40).
Dechra Pharmaceuticals plc (LON:DPH) traded down 0.41% on Tuesday, hitting GBX 730.00. The stock had a trading volume of 84,436 shares. Dechra Pharmaceuticals plc has a 52-week low of GBX 655.00 and a 52-week high of GBX 755.00. The stock’s 50-day moving average is GBX 708.5 and its 200-day moving average is GBX 697.. The company’s market cap is £636.6 million.
Dechra Pharmaceuticals PLC is a United Kingdom-based veterinary pharmaceutical company. The Company is engaged in developing, manufacturing, distributing, selling and marketing of animal products to the veterinary industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.